These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11241900)

  • 1. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.
    Braunschweig R; Yan P; Guilleret I; Delacretaz F; Bosman FT; Mihaescu A; Benhattar J
    Diagn Cytopathol; 2001 Mar; 24(3):174-80. PubMed ID: 11241900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitfalls in TRAP assay in routine detection of malignancy in effusions.
    Braunschweig R; Guilleret I; Delacrétaz F; Bosman FT; Mihaescu A; Benhattar J
    Diagn Cytopathol; 2001 Oct; 25(4):225-30. PubMed ID: 11599105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
    Hansson M; Zendehrokh N; Ohyashiki J; Ohyashiki K; Westman UB; Roos G; Dejmek A
    Arch Pathol Lab Med; 2008 Dec; 132(12):1896-902. PubMed ID: 19061286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the human telomerase RNA component by in situ hybridization in cells from body fluids.
    Nieh S; Chen SF; Fu E; Jan CI; Lee WH
    Acta Cytol; 2005; 49(1):31-7. PubMed ID: 15717752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytological diagnosis and telomerase activity of cells in effusions of body cavities.
    Toshima S; Arai T; Yasuda Y; Takaya T; Ito Y; Hayakawa K; Shibuya C; Yoshimi N; Shibayama M; Kashiki Y
    Oncol Rep; 1999; 6(1):199-203. PubMed ID: 9864428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes.
    Zendehrokh N; Dejmek A
    Mod Pathol; 2005 Feb; 18(2):189-96. PubMed ID: 15389260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
    Lee WY
    Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression analysis of the catalytic subunit of human telomerase (hEST2) in the differential diagnosis of serous effusions.
    Nagel H; Schlott T; Schulz GM; Droese M
    Diagn Mol Pathol; 2001 Mar; 10(1):60-5. PubMed ID: 11277397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase activity in pleural effusions: diagnostic significance.
    Yang CT; Lee MH; Lan RS; Chen JK
    J Clin Oncol; 1998 Feb; 16(2):567-73. PubMed ID: 9469342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
    Adell E; Dejmek A
    Diagn Cytopathol; 2014 Dec; 42(12):1051-7. PubMed ID: 24692425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase enzyme activity as a diagnostic tool to distinguish effusions of malignant and benign origin.
    Spangler EA; Rogers KS; Thomas JS; Pustejovsky D; Boyd SL; Shippen DE
    J Vet Intern Med; 2000; 14(2):146-50. PubMed ID: 10772485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expressions of human telomerase mRNA component (hTERC) and telomerase reverse transcriptase (hTERT) mRNA in effusion cytology.
    Hiroi S; Nakanishi K; Kawai T
    Diagn Cytopathol; 2003 Oct; 29(4):212-6. PubMed ID: 14506674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center.
    Lobo C; Costa J; Petronilho S; Monteiro P; Leça L; Schmitt F
    Diagn Cytopathol; 2021 May; 49(5):596-605. PubMed ID: 32339444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of hyperdiploid malignant cells in body cavity effusions by fluoresence in situ hybridization on ThinPrep slides.
    Florentine BD; Sanchez B; Raza A; Frankel K; Martin SE; Kovacs B; Felix JC
    Cancer; 1997 Oct; 81(5):299-308. PubMed ID: 9349518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and categorization of malignant effusions: A 6-year review from a single academic institution.
    Lew M; Cantley R; Heider A; Jing X
    Diagn Cytopathol; 2021 May; 49(5):615-621. PubMed ID: 32275354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of telomerase activity between malignant and tuberculous pleural effusions.
    Maneechotesuwan K; Lertworawiwat A; Tscheikuna J; Wamanuttajinda V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S46-54. PubMed ID: 17718245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase activity in body cavity fluid and peritoneal washings in uterine and ovarian cancer.
    Murakami J; Nagai N; Ohama K
    J Int Med Res; 1998; 26(3):129-39. PubMed ID: 9718467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
    Pomjanski N; Motherby H; Buckstegge B; Knops K; Rohn BL; Böcking A
    Anal Quant Cytol Histol; 2001 Apr; 23(2):151-60. PubMed ID: 11332082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis.
    Gupta P; Pandey T; Gautam U; Rajwanshi A; Srinivasan R; Gupta N; Rohilla M; Varma N; Dey P
    Diagn Cytopathol; 2021 May; 49(5):647-656. PubMed ID: 33629825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase activity in benign and malignant cytologic fluids.
    Mu XC; Brien TP; Ross JS; Lowry CV; McKenna BJ
    Cancer; 1999 Apr; 87(2):93-9. PubMed ID: 10227600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.